ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Ime in priimekABBVON

UvrstitevNo.3358

Tržna kapitalizacija$0.00

Popolnoma razredčena tržna kapitalizacija$0.00

Tržni delež%

Volumen trgovanja/tržna kapitalizacija (24h)912,200.21%

Razpoložljivi obtok125.85292924

Največja ponudba0

Skupna ponudba125.85292924

Hitrost kroženja%

Datum izdaje--

Cena, po kateri je bilo sredstvo prvič izdano--

Najvišja vrednost vseh časov237.64005999136555,2026-03-05

Najnižja cena193.3720963640878,2026-04-29

Javna veriga blokovETH

UvodAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Panoga

Družbeni mediji

• Uradna spletna stran
• Raziskovalec blokov

etfindex:mc_etfindex_sourceOmejitev odgovornosti: Podatke zagotavlja cmc in se ne smejo obravnavati kot naložbeni nasveti.